The upcoming EU Health Technology Assessment (HTA) legislation promises to revolutionise market access for pharmaceutical manufacturers across the EU. Designed to streamline the evaluation process for health technologies, this legislation demands a strategic approach from manufacturers to ensure compliance and competitiveness in the market.
In our latest webinar, held on 8th May 2024, Dr. Paul Craddy and Dr. Graham Foxon, delved into the critical transition from strategic planning to actionable steps. Drawing on their extensive experience, Remap’s managing directors guided participants through the intricacies of incorporating EU HTA considerations into their long-term activities.
To view the webinar on demand, please click below:
If you have any questions or would like to discuss the topic in more detail, please reach out.